Profile data is unavailable for this security.
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
- Revenue in EUR (TTM)37.55bn
- Net income in EUR5.81bn
- Incorporated1994
- Employees99.41k
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Kadmon Holdings Inc | -5.43% | 1.76bn |
| Translate Bio Inc | -5.21% | 3.04bn |
| Tidal Therapeutics Inc | -2.93% | 470.00m |
| Kymab Group Ltd | 4.37% | 1.45bn |
| Kiadis Pharma NV | 6.28% | 254.17m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurofins Scientific SE | 6.39bn | 1.07bn | 23.76bn | 49.07k | 23.45 | 5.84 | 15.59 | 3.72 | 5.31 | 4.11 | 31.80 | 21.32 | 0.7628 | 30.45 | 5.62 | 123,994.50 | 13.17 | 6.28 | 16.35 | 8.02 | 30.17 | 21.25 | 17.27 | 10.13 | 1.28 | 14.40 | 0.3925 | 14.76 | 19.20 | 22.77 | 116.43 | 38.20 | 16.02 | 36.22 |
| Lonza Group AG | 3.65bn | 472.41m | 51.22bn | 14.41k | 108.71 | 7.65 | 56.13 | 14.02 | 6.88 | 9.52 | 53.25 | 97.83 | 0.2732 | -- | -- | 240,386.90 | 3.55 | 5.12 | 4.32 | 6.35 | 41.95 | 38.95 | 13.00 | 13.11 | -- | 26.49 | 0.3319 | 33.19 | 7.15 | 3.46 | 12.83 | 21.39 | 29.81 | 5.31 |
| GlaxoSmithKline plc | 38.31bn | 5.11bn | 82.28bn | 94.07k | 16.15 | 4.59 | 11.52 | 2.15 | 0.8696 | 0.8696 | 6.52 | 3.06 | 0.407 | 1.67 | 4.68 | 349,701.30 | 6.27 | 6.21 | 9.78 | 10.38 | 67.75 | 68.84 | 15.40 | 12.69 | 0.5254 | 10.04 | 0.5415 | 113.09 | 1.02 | 7.35 | 23.77 | -7.35 | 3.33 | 0.00 |
| Sanofi SA | 37.55bn | 5.81bn | 103.62bn | 99.41k | 17.73 | 1.62 | 14.03 | 2.76 | 4.63 | 4.63 | 29.94 | 50.49 | 0.3292 | 1.34 | 5.36 | 377,680.80 | 5.10 | 4.98 | 6.12 | 5.97 | 67.63 | 68.13 | 15.49 | 14.73 | 1.06 | 28.31 | 0.2551 | 69.80 | -0.6962 | 1.40 | 323.60 | 22.79 | -5.28 | 1.78 |
| Novo Nordisk A/S | 17.47bn | 5.97bn | 151.22bn | 45.97k | 33.17 | 21.99 | 22.28 | 8.66 | 19.13 | 19.13 | 55.98 | 28.85 | 0.8831 | 1.21 | 5.02 | 2,904,769.00 | 30.16 | 35.30 | 57.56 | 67.18 | 82.96 | 84.10 | 34.15 | 33.51 | 0.8012 | -- | 0.1735 | 50.32 | 4.04 | 3.30 | 8.18 | 3.87 | 28.08 | 7.29 |
| AstraZeneca plc | 25.18bn | 3.22bn | 155.39bn | 76.10k | 41.05 | 9.85 | 26.87 | 6.17 | 2.10 | 2.10 | 16.43 | 8.74 | 0.4421 | 1.69 | 5.19 | 284,116.80 | 5.64 | 3.88 | 8.22 | 5.46 | 76.23 | 80.97 | 12.76 | 10.19 | 1.01 | 3.46 | 0.6366 | 141.03 | 9.16 | 1.50 | 139.40 | 2.50 | -1.34 | 0.2156 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 11 Aug 2021 | 63.18m | 5.00% |
| Norges Bank Investment Managementas of 31 Dec 2020 | 28.28m | 2.24% |
| The Vanguard Group, Inc.as of 03 Sep 2021 | 27.68m | 2.19% |
| BlackRock Fund Advisorsas of 02 Sep 2021 | 19.29m | 1.53% |
| FIL Investment Advisors (UK) Ltd.as of 31 Jul 2021 | 12.17m | 0.96% |
| Lyxor International Asset Management SASas of 01 Sep 2021 | 11.72m | 0.93% |
| Amundi Asset Management SA (Investment Management)as of 14 Sep 2021 | 11.53m | 0.91% |
| BlackRock Investment Management LLCas of 16 Sep 2021 | 10.75m | 0.85% |
| BlackRock Advisors (UK) Ltd.as of 02 Sep 2021 | 10.64m | 0.84% |
| Fidelity Management & Research Co. LLCas of 31 Jul 2021 | 10.21m | 0.81% |
